Elevance Health (ELV) to Release Quarterly Earnings on Wednesday

Elevance Health (NYSE:ELV) is anticipated to release its Q4 2025 results before the market opens on Wednesday, January 28th. Analysts expect Elevance Health to post earnings of $3.07 per share and revenue of $49.5216 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 8:30 AM ET.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.03 by $1.00. The company had revenue of $50.09 billion during the quarter, compared to analyst estimates of $49.26 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the company earned $8.37 earnings per share. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.

Elevance Health Price Performance

Shares of NYSE ELV opened at $366.62 on Wednesday. The firm has a market capitalization of $81.48 billion, a P/E ratio of 14.99, a P/E/G ratio of 1.93 and a beta of 0.51. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The stock’s 50-day simple moving average is $346.57 and its two-hundred day simple moving average is $328.18. Elevance Health has a twelve month low of $273.71 and a twelve month high of $458.75.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sei Investments Co. increased its holdings in Elevance Health by 7.7% during the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after purchasing an additional 11,745 shares during the period. Glenview Trust co grew its position in shares of Elevance Health by 41.5% in the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after buying an additional 475 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Elevance Health by 6.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after buying an additional 4,272 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Elevance Health by 5.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after acquiring an additional 2,012 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Elevance Health by 111.8% in the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after acquiring an additional 23,180 shares during the period. 89.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ELV has been the subject of several research analyst reports. Bank of America lifted their price target on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, October 10th. Sanford C. Bernstein restated an “outperform” rating and issued a $431.00 target price on shares of Elevance Health in a research report on Tuesday, January 6th. Truist Financial set a $400.00 price target on shares of Elevance Health in a research report on Tuesday, October 14th. Guggenheim lifted their price target on shares of Elevance Health from $360.00 to $398.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Finally, Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Thirteen investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $400.85.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.